Comparison between tools for measuring breathlessness: Cross‐sectional validation of the Japanese version of the Dyspnoea‐12. (3rd August 2021)

• Record Type: Journal Article
• Authors: Nishimura, Koichi; Oga, Toru; Nakayasu, Kazuhito; Taniguchi, Hiroyuki; Ogawa, Tomoya; Watanabe, Fumiko; Arizono, Shinichi; Kusunose, Masaaki; Sanda, Ryo; Shibayama, Ayumi; Okamoto, Sawako; Yorke, Janelle
• Is Part Of: Clinical respiratory journal. Volume 15:Number 11(2021)
• Page Start: 1201
• Page End: 1209
• Publication Date: 2021-08-03
• Subjects: chronic obstructive pulmonary disease (COPD) -- Dyspnoea‐12 (D‐12) -- Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI) -- St. George's Respiratory Questionnaire (SGRQ); Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13427
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Introduction: The Dyspnoea‐12 (D‐12) is a brief, easy to complete questionnaire for measuring breathlessness. Objectives: To facilitate further efforts to measure dyspnoea in real clinical settings, the authors aimed to develop and validate a Japanese version of the D‐12 and also compare the D‐12 with the Baseline Dyspnea Index (BDI) and the Activity component of the St. George's Respiratory Questionnaire (SGRQ). Methods: The standardized procedure in accordance with international guidelines was used to create the translation. A validation study with a cross‐sectional observational design was conducted on 122 subjects with stable chronic obstructive pulmonary disease (COPD). Results: The internal consistency of the D‐12 was high (Cronbach's coefficient α = 0.883) and similar to that of the BDI ( α = 0.824) and SGRQ Activity ( α = 0.872). The relationships between tools were statistically significant (| R s | = 0.53 to 0.66). Although the scores obtained from all three tools were skewed toward the milder end of the respective scales, this deviation was most prominent in the D‐12 with a floor effect of 48.4%. Conclusion: The Japanese version of the D‐12 was successfully validated, but we should be careful of any floor effect and marked skew to the mild end of the scale, especially in subjects with mild COPD.